Impact of Bone-Marrow Aspirate Injections in Knee Arthroscopy

NARecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 30, 2026

Primary Completion Date

April 30, 2028

Study Completion Date

April 30, 2029

Conditions
Chondral Lesion of the KneeMeniscal InjuriesCartilage Defects of the KneeOsteoarthritis (OA) of the Knee
Interventions
BIOLOGICAL

Bone Marrow Aspirate (BMA)

Bone marrow aspirate (BMA) is being investigated as an augmentation to arthroscopic debridement surgery of the knee to treat conditions such as meniscal injuries, chondral defects, and low-grade osteoarthritis.

PROCEDURE

Arthroscopic Debridement Surgery

Arthroscopic debridement surgery of the knee is performed to treat conditions such as meniscal injuries, chondral defects, and low-grade osteoarthritis.

OTHER

Saline

Patients in the control arm of the study will receive arthroscopic debridement surgery along with a saline injection. This will be compared to the experimental arm, in which patients will receive arthroscopic debridement surgery along with a bone marrow aspirate injection.

Trial Locations (1)

10021

RECRUITING

Hospital for Special Surgery, New York

All Listed Sponsors
lead

Hospital for Special Surgery, New York

OTHER